{"success":true,"data":{"pressRelease":{"id":"145531","rtpr_id":"nACSxkGTla-20260916","ticker":"GUTS","exchange":"NASDAQ","all_tickers":["GUTS"],"title":"GUTS ALERT: Securities Fraud Class Action Launched Against Fractyl Health, Inc. - October 20, 2026 Deadline","author":"ACCESSWIRE","published_at":"2026-09-16T17:22:00.267Z","article_body":"NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) /\nSeptember 16, 2026 / Levi & Korsinsky, LLP announces that a securities class\naction lawsuit has been filed on behalf of investors who purchased or\notherwise acquired Fractyl Health, Inc. (NASDAQ:GUTS) securities.\n\nIf you suffered a loss on your Fractyl Health, Inc. investment and would like\nto explore a potential recovery under the federal securities laws, Learn about\nFractyl Health, Inc. Class Action (https://pr.report/qbxz) or contact Joseph\nE. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to\nspeak to our team of experienced shareholder advocates.\n\nTHE LAWSUIT: A class action securities lawsuit was filed against Fractyl\nHealth, Inc. that seeks to recover losses of shareholders who were adversely\naffected by alleged securities fraud between January 13, 2025 and January 29,\n2026.\n\nCASE DETAILS: The filed complaint alleges that defendants made false\nstatements and/or concealed that: (i) Revita was less effective than\ndefendants had led investors to believe, and/or operational issues at one or\nmore of the REMAIN-1 Midpoint Cohort's clinical sites compromised the\nintegrity of its efficacy results; (ii) accordingly, Revita's clinical,\nregulatory, and commercial prospects were overstated, as was the REMAIN-1\nMidpoint Cohort's ability to assess Revita's efficacy; and (iii) as a result,\ndefendants' public statements were materially false and misleading at all\nrelevant times.\n\nWHAT'S NEXT? If you purchased Fractyl Health, Inc. stock during the relevant\ntime frame - even if you still hold your shares, learn about your rights to\nseek a recovery (https://pr.report/qby0). There is no cost or obligation to\nparticipate.\n\nWHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has\nestablished itself as a nationally-recognized securities litigation firm that\nhas secured hundreds of millions of dollars for aggrieved shareholders and\nbuilt a track record of winning high-stakes cases. The firm has extensive\nexpertise representing investors in complex securities litigation and a team\nof over 70 employees to serve our clients. For seven years in a row, Levi &\nKorsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as\none of the top securities litigation firms in the United States. Attorney\nAdvertising. Prior results do not guarantee similar outcomes.\n\nCONTACT:\nLevi & Korsinsky, LLP\nJoseph E. Levi, Esq.\nEd Korsinsky, Esq.\n33 Whitehall Street, 27th Floor\nNew York, NY 10004\njlevi@levikorsinsky.com\nTel: (212)363-7500\nFax: (212) 363-7171\n\nSOURCE: Levi & Korsinsky, LLP\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/guts-alert-securities-fraud-class-action-launched-against-fracty-1221792)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACSxkGTla-20260916","title":"GUTS ALERT: Securities Fraud Class Action Launched Against Fractyl Health, Inc. - October 20, 2026 Deadline","author":"ACCESSWIRE","ticker":"GUTS","created":"2026-09-16T17:22:00.267Z","tickers":["GUTS"],"exchange":"NASDAQ","article_body":"NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) /\nSeptember 16, 2026 / Levi & Korsinsky, LLP announces that a securities class\naction lawsuit has been filed on behalf of investors who purchased or\notherwise acquired Fractyl Health, Inc. (NASDAQ:GUTS) securities.\n\nIf you suffered a loss on your Fractyl Health, Inc. investment and would like\nto explore a potential recovery under the federal securities laws, Learn about\nFractyl Health, Inc. Class Action (https://pr.report/qbxz) or contact Joseph\nE. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to\nspeak to our team of experienced shareholder advocates.\n\nTHE LAWSUIT: A class action securities lawsuit was filed against Fractyl\nHealth, Inc. that seeks to recover losses of shareholders who were adversely\naffected by alleged securities fraud between January 13, 2025 and January 29,\n2026.\n\nCASE DETAILS: The filed complaint alleges that defendants made false\nstatements and/or concealed that: (i) Revita was less effective than\ndefendants had led investors to believe, and/or operational issues at one or\nmore of the REMAIN-1 Midpoint Cohort's clinical sites compromised the\nintegrity of its efficacy results; (ii) accordingly, Revita's clinical,\nregulatory, and commercial prospects were overstated, as was the REMAIN-1\nMidpoint Cohort's ability to assess Revita's efficacy; and (iii) as a result,\ndefendants' public statements were materially false and misleading at all\nrelevant times.\n\nWHAT'S NEXT? If you purchased Fractyl Health, Inc. stock during the relevant\ntime frame - even if you still hold your shares, learn about your rights to\nseek a recovery (https://pr.report/qby0). There is no cost or obligation to\nparticipate.\n\nWHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has\nestablished itself as a nationally-recognized securities litigation firm that\nhas secured hundreds of millions of dollars for aggrieved shareholders and\nbuilt a track record of winning high-stakes cases. The firm has extensive\nexpertise representing investors in complex securities litigation and a team\nof over 70 employees to serve our clients. For seven years in a row, Levi &\nKorsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as\none of the top securities litigation firms in the United States. Attorney\nAdvertising. Prior results do not guarantee similar outcomes.\n\nCONTACT:\nLevi & Korsinsky, LLP\nJoseph E. Levi, Esq.\nEd Korsinsky, Esq.\n33 Whitehall Street, 27th Floor\nNew York, NY 10004\njlevi@levikorsinsky.com\nTel: (212)363-7500\nFax: (212) 363-7171\n\nSOURCE: Levi & Korsinsky, LLP\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/guts-alert-securities-fraud-class-action-launched-against-fracty-1221792)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-09-16T17:22:00.316692622Z","server_sent_at_ms":1789579320316},"received_at":"2026-09-16T17:22:00.374Z","source_url":"https://www.accessnewswire.com/newsroom/en/business-and-professional-services/guts-alert-securities-fraud-class-action-launched-against-fracty-1221792"},"analysis":{"id":"134363","press_release_id":"145531","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["Class action alleges operational issues at REMAIN-1 Midpoint Cohort clinical sites compromised the integrity of Revita efficacy results","Alleges Fractyl overstated Revita's clinical, regulatory, and commercial prospects during the January 2025-January 2026 class period"],"eventType":"legal_litigation","narrative":"Levi & Korsinsky announced that a securities class action has been filed against Fractyl Health on behalf of investors who purchased GUTS securities, covering a class period from January 13, 2025 through January 29, 2026, with a lead plaintiff deadline of October 20, 2026.\n\nThe complaint alleges defendants concealed that Revita was less effective than represented and that operational issues at one or more REMAIN-1 Midpoint Cohort clinical sites compromised the integrity of its efficacy results, overstating Revita's clinical, regulatory, and commercial prospects.\n\nThis release is plaintiff-firm solicitation rather than an issuer disclosure — no certified class or settlement exists — though the underlying trial data-integrity allegations are a substantive overhang for GUTS's lead pipeline asset.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress; watch for independent GUTS disclosure on REMAIN-1 data integrity instead."},"keyFigures":{"customDimensions":{"class_period_end":"January 29, 2026","class_period_start":"January 13, 2025","lead_plaintiff_deadline":"October 20, 2026"}},"quotedText":"(i) Revita was less effective than\ndefendants had led investors to believe, and/or operational issues at one or\nmore of the REMAIN-1 Midpoint Cohort's clinical sites compromised the\nintegrity of its efficacy results","namedEntities":{"people":[{"name":"Joseph E. Levi, Esq.","role":"Attorney / contact at Levi & Korsinsky"},{"name":"Ed Korsinsky, Esq.","role":"Attorney at Levi & Korsinsky"}],"products":["Revita","REMAIN-1 Midpoint Cohort"],"companies":[{"name":"Fractyl Health, Inc.","ticker":"GUTS","relationship":"defendant / class action target"},{"name":"Levi & Korsinsky, LLP","relationship":"plaintiff law firm"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm solicitation issued by Levi & Korsinsky announcing a securities class action filing and seeking lead-plaintiff contacts. No certified class, no settlement, and no new disclosure from the issuer; this is litigation-marketing boilerplate despite the real underlying filing."},"tickerRelevance":{"others":[],"primary":"GUTS"},"globalImportance":20,"audienceRelevance":12,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap biotech","eventGravity":"securities class action filing announcement via plaintiff-firm solicitation","certifiedClass":false,"issuerAuthored":false,"underlyingSignal":"clinical trial data-integrity allegations against lead asset Revita","settlementAnnounced":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Levi & Korsinsky announced that a securities class action has been filed against Fractyl Health on behalf of investors who purchased GUTS securities, covering a class period from January 13, 2025 through January 29, 2026, with a lead plaintiff deadline of October 20, 2026.\n\nThe complaint alleges defendants concealed that Revita was less effective than represented and that operational issues at one or more REMAIN-1 Midpoint Cohort clinical sites compromised the integrity of its efficacy results, overstating Revita's clinical, regulatory, and commercial prospects.\n\nThis release is plaintiff-firm solicitation rather than an issuer disclosure — no certified class or settlement exists — though the underlying trial data-integrity allegations are a substantive overhang for GUTS's lead pipeline asset.","key_figures":{"customDimensions":{"class_period_end":"January 29, 2026","class_period_start":"January 13, 2025","lead_plaintiff_deadline":"October 20, 2026"}},"named_entities":{"people":[{"name":"Joseph E. Levi, Esq.","role":"Attorney / contact at Levi & Korsinsky"},{"name":"Ed Korsinsky, Esq.","role":"Attorney at Levi & Korsinsky"}],"products":["Revita","REMAIN-1 Midpoint Cohort"],"companies":[{"name":"Fractyl Health, Inc.","ticker":"GUTS","relationship":"defendant / class action target"},{"name":"Levi & Korsinsky, LLP","relationship":"plaintiff law firm"}],"dollarAmounts":[]},"model_name":"glm-5.3-flash","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-16T17:22:33.546Z","global_importance":20,"audience_relevance":12,"importance_components":{"tickerTier":"small-cap biotech","eventGravity":"securities class action filing announcement via plaintiff-firm solicitation","certifiedClass":false,"issuerAuthored":false,"underlyingSignal":"clinical trial data-integrity allegations against lead asset Revita","settlementAnnounced":false}},"durationMs":33160,"modelName":"glm-5.3-flash"}}